Prevalence of Incidental Findings in Pharmacogenomic Panel Testing

Introduction

• Pharmacogenomic (PGx) testing can guide medication management across many disease states
  • PGx variation can impact medication efficacy and/or tolerability
  • PGx panels can include genes such as: CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, G6PD, NUDT15, RYR1, SLCO1B1, TPMT, UGT1A1, VKORC1
• Genes commonly included on PGx panels can have overlap with medication management implications and disease risk
  • PGx genes can have overlapping disease risk or a disease state risk associated with medication use (Table 1) that may require additional education or testing
• To determine the proportion of patients that may warrant additional education regarding the overlapping disease risk and drug-gene interaction, an analysis was conducted to determine the prevalence of these disease risk variants after PGx panel testing